Last reviewed · How we verify
Intra-Arterial TNK and Albumin
Intra-Arterial TNK and Albumin is a Thrombolytic agent with albumin carrier Small molecule drug developed by Tianjin Huanhu Hospital. It is currently in Phase 3 development for Acute ischemic stroke (intra-arterial administration), Acute arterial occlusion.
Intra-arterial TNK (tenecteplase) and albumin work together to deliver thrombolytic therapy directly to occluded arteries while albumin may enhance drug delivery and reduce systemic toxicity.
Intra-arterial TNK (tenecteplase) and albumin work together to deliver thrombolytic therapy directly to occluded arteries while albumin may enhance drug delivery and reduce systemic toxicity. Used for Acute ischemic stroke (intra-arterial administration), Acute arterial occlusion.
At a glance
| Generic name | Intra-Arterial TNK and Albumin |
|---|---|
| Sponsor | Tianjin Huanhu Hospital |
| Drug class | Thrombolytic agent with albumin carrier |
| Target | Fibrin; plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Neurology |
| Phase | Phase 3 |
Mechanism of action
TNK is a fibrin-specific thrombolytic agent that dissolves blood clots by converting plasminogen to plasmin. When administered intra-arterially with albumin as a carrier or adjuvant, this combination aims to achieve higher local drug concentrations at the site of arterial occlusion while potentially reducing systemic exposure and associated bleeding complications. Albumin may also provide neuroprotection and improve drug stability.
Approved indications
- Acute ischemic stroke (intra-arterial administration)
- Acute arterial occlusion
Common side effects
- Intracranial hemorrhage
- Systemic bleeding
- Reperfusion injury
- Allergic reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra-Arterial TNK and Albumin CI brief — competitive landscape report
- Intra-Arterial TNK and Albumin updates RSS · CI watch RSS
- Tianjin Huanhu Hospital portfolio CI
Frequently asked questions about Intra-Arterial TNK and Albumin
What is Intra-Arterial TNK and Albumin?
How does Intra-Arterial TNK and Albumin work?
What is Intra-Arterial TNK and Albumin used for?
Who makes Intra-Arterial TNK and Albumin?
What drug class is Intra-Arterial TNK and Albumin in?
What development phase is Intra-Arterial TNK and Albumin in?
What are the side effects of Intra-Arterial TNK and Albumin?
What does Intra-Arterial TNK and Albumin target?
Related
- Drug class: All Thrombolytic agent with albumin carrier drugs
- Target: All drugs targeting Fibrin; plasminogen
- Manufacturer: Tianjin Huanhu Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular; Neurology
- Indication: Drugs for Acute ischemic stroke (intra-arterial administration)
- Indication: Drugs for Acute arterial occlusion
- Compare: Intra-Arterial TNK and Albumin vs similar drugs
- Pricing: Intra-Arterial TNK and Albumin cost, discount & access